Search PubMed⌕ Search

Biomedical subjects

B Magnani

Publications and source records attributed to B Magnani.

At least 199 records · Page 11Linked to original sources
PubMed1986

Antiarrhythmic efficacy of propafenone: evaluation of effective plasma levels following single and multiple doses.

In 11 patients with stable premature ventricular beats, the kinetics of single (150 and 300 mg) and multiple (150 mg t.i.d. and 300 mg t.i.d.) oral doses of propafenone were studied with reference to arrhythmia suppression. During the acute phase detectable plasma levels of the drug were achieved only with the higher dose. In 8 out of 10 patients the antiarrhythmic effect was obtained with the 300 mg dose, which was found to predict responsiveness at steady-state. During the chronic phase, antiarrhythmic efficacy was obtained with the lower dose regimen (150 mg t.i.d.) in half of those patients. A wide range of effective plasma levels was observed. The previously suggested therapeutic range (0.5-2.0 micrograms/ml) was not adequate in predicting either antiarrhythmic activity or adverse effects. The results show the role of propafenone metabolites in determining total antiarrhythmic action.

Administration, Oral↗
PubMed1986

[Risk of obstruction of secondary vessels in coronary angioplasty].

To define the risk of side branch occlusion during percutaneous transluminal coronary angioplasty (PTCA), 99 consecutive procedures, performed on 92 patients, were examined. In 77 of them side branches existed, originating from the stenosed segment; analysis was performed on 65 successful procedures (success rate = 84.4%). The 121 side branches were divided as follows: 53 (43.8%) originating from the stenosis itself (group A), of which 32 small in size (less than 1 mm) and 21 "moderate" (greater than or equal to 1 mm); 68 (56.2%) originating in the immediate vicinity of the stenosis (group B) of which 23 small and 45 moderate. After PTCA 3 side branches were occluded (2.5%): a small 1 of group A and 2 (1 small and 1 moderate) of group B. Three side branches (2.5%) all of group B, 1 small and 2 moderate, became stenotic in their take-off. In one only patient who had a side branch occlusion a slight CK-MB elevation (25 mU/ml) occurred together with a Q wave appearance in the aVL lead. In conclusion, side branches at risk are frequently present (in our population they account for 83.7% of the patients) but the real incidence of damage of these branches after PTCA is quite low, without any considerable difference between groups A and B, and significant clinical consequences are usually rare.

Angioplasty, Balloon↗
PubMed1986

Captopril in mild heart failure: preliminary observations of a long-term, double-blind, placebo-controlled multicentre trial.

Ninety-four patients on digitalis treatment for chronic congestive heart failure (NYHA class II-III) were enrolled for a 12 month trial in a random, double-blind, placebo-controlled study. After a placebo run-in period, patients were assigned to placebo or captopril 25 mg t.i.d. Digitalis was continued while diuretics were withdrawn. Clinical status, exercise capacity, cardiac dimensions and performance were evaluated with a full physical examination, 12 lead ECG, chest X-ray, 24 hour Holter monitoring, bicycle effort capacity, M-mode echocardiography and radionuclide ventriculography at 1, 2 and 3 weeks and 1, 2, 3, 6 and 12 months. There were no significant differences in the trend of survival curves after six months follow-up between the captopril or placebo treatment groups. Patients treated with captopril, without the addition of diuretics, had an improvement in NYHA class (P less than 0.01), an increase in exercise capacity (P less than 0.025), a decrease in cardiothoracic ratio (P less than 0.025) and an increase of echocardiographic left ventricular contractility (P less than 0.005). Only four patients treated with captopril were withdrawn from the follow-up for allergic side effects. Preliminary results at 6 months prove that captopril, compared to placebo, is useful in mild to moderate heart failure.

Adult↗
PubMed1986

[Percutaneous embolization of a Blalock-Taussig shunt in an adult].

The technique used in percutaneous embolization of a Blalock-Taussig shunt in a 35-year-old male is described. After selective catheterization of the left subclavian artery leading to the shunt, some spring coils were inserted which completely occluded the shunt. The choice of occluding material is discussed.

Adult↗
PubMed1986

Nifedipine compared with verapamil in unstable angina pectoris.

A randomized trial was performed in 22 patients with unstable angina to compare the efficacy of oral verapamil with nifedipine in reducing symptomatic ischaemic episodes. The trial consisted of a 48 h control period, a 96 h treatment period with nifedipine (20 mg every 6 h) or verapamil (120 mg every 6 h), and a follow-up period. Patients who had a minimum of four symptomatic ischaemic episodes during the control period were entered into the trial. Asymptomatic ischaemic episodes were evaluated by Holter monitoring. Coronary angiography was performed at the end of the treatment period. Both nifedipine and verapamil significantly reduced the mean number of daily symptomatic ischaemic episodes (p less than 0.01) and the total number of ischaemic episodes (p less than 0.03). This study confirmed the high degree of efficacy of both nifedipine and verapamil in reducing the number of ischaemic episodes during short-term treatment of unstable angina. Nevertheless, a significant number of myocardial infarctions occurred in these patients, and some required subsequent coronary bypass graft operations.

Adult↗
PubMed1986

Effects of oral nisoldipine in ischemic heart disease. A radioisotopic study.

UNLABELLED: Nisoldipine (Bay k 5552) is the most potent calcium antagonist known; yet, its cardiovascular effects in man are still under investigation. In the present study 10 consecutive male patients with isolated significant lesion on the left anterior descending coronary artery underwent ECG gated nuclear ventriculography at rest and during submaximal bicycle exercise in the supine position. Following the oral administration of 10 mg of nisoldipine the study was repeated at 90 and 180 min, with the patient in the same position and with the same work load. Left ventricular ejection fraction (EF), end-systolic blood volume index (ESBVI), end-diastolic blood volume index (EDBVI), stroke volume index (SVI), peak left ventricular ejection rate (PER), peak left ventricular filling rate (PFR), time to PER (TPER) and time to PFR (TPFR), and systemic vascular resistance (SVR) were evaluated, regional wall motion was also judged by three independent observers. At rest, a significant (p less than 0.001) decrease of SVR and systolic blood pressure (SBP) was found; a significant (p less than 0.001) decrease of diastolic blood pressure (DBP) and an increase (p less than 0.05) of heart rate (HR), EDBVI and PFR were also registered, the other indexes resulting unaffected. During exercise the reduction of SVR was confirmed. An improvement of the wall motion was found in 4 out of 11 segments at rest and in 9 out of 17 under stress. CONCLUSIONS: nisoldipine shows a predominant peripheral effect, without impairment of cardiac contractility; the improvement of the wall motion of the ischemic regions achieved at similar levels of double product suggests an increased coronary blood flow and a metabolic amelioration.

Administration, Oral↗